文献速递心脑血管急症创伤与烧伤重症综合管理与镇静镇痛

新型口服抗凝药与华法林在创伤性脑损伤后颅内出血患者中的结局比较

The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI.
PubMed 文献 · J Trauma Acute Care Surg · 2018-01-01
一句话结论在轻中度创伤性脑损伤合并颅内出血患者中,伤前使用新型口服抗凝药者的血肿进展、神经外科干预和死亡率均高于华法林使用者。

该研究基于2014至2016年前瞻性维护的创伤性脑损伤数据库,纳入使用抗凝药的创伤性脑损伤合并颅内出血患者,按倾向评分1:2匹配为新型口服抗凝药组(70例)与华法林组(140例)。匹配后两组年龄、致伤机制、格拉斯哥昏迷评分、损伤严重度评分及颅内出血类型和大小均相似。结果显示新型口服抗凝药组血肿进展率、神经外科干预率、死亡率和ICU住院时间均高于华法林组,而总住院时间和出院至专业护理机构的比例无差异;在格拉斯哥昏迷评分≤8分的重型创伤性脑损伤亚组中,两组血肿进展、神经外科干预和死亡率相似。作者认为新型口服抗凝药总体出血风险高,在合并颅内出血的头部创伤中可能有害。

要点

  • 轻中度创伤性脑损伤合并颅内出血患者中,伤前使用新型口服抗凝药者血肿进展率高于华法林使用者(P=0.03)。
  • 同一匹配人群中,新型口服抗凝药组神经外科干预率(P=0.04)和死亡率(P=0.04)均高于华法林组。
  • 新型口服抗凝药组ICU住院时间较华法林组更长(P=0.04),但总住院时间(P=0.22)和出院至专业护理机构比例(P=0.14)无差异。
  • 在格拉斯哥昏迷评分≤8分的重型创伤性脑损伤亚组中,两组血肿进展(P=0.59)、神经外科干预(P=0.62)和死亡率(P=0.81)相似。
  • 作者认为新型口服抗凝药总体出血风险高,在合并颅内出血的头部创伤中可能有害,并建议开发针对新型口服抗凝药的逆转剂及实施严格的逆转方案。

适用人群与场景

  • 2014至2016年该中心前瞻性维护的创伤性脑损伤数据库中,所有使用抗凝药且合并颅内出血的创伤性脑损伤患者。
  • 匹配分析人群为70例伤前使用新型口服抗凝药者与140例伤前使用华法林者,按倾向评分1:2匹配。
  • 亚组分析为格拉斯哥昏迷评分≤8分的重型创伤性脑损伤患者。

研究设计与关键结果

  • 研究类型为基于前瞻性维护创伤性脑损伤数据库的分析,共分析1459例创伤性脑损伤患者,经倾向评分1:2匹配后纳入210例(新型口服抗凝药组70例,华法林组140例)。
  • 匹配后两组年龄(P=0.21)、致伤机制(P=0.61)、格拉斯哥昏迷评分(P=0.54)、损伤严重度评分(P=0.62)及颅内出血类型和大小(P=0.09)相似。
  • 新型口服抗凝药组较华法林组血肿进展率更高(P=0.03)、神经外科干预率更高(P=0.04)、死亡率更高(P=0.04)、ICU住院时间更长(P=0.04)。
  • 两组总住院时间(P=0.22)和出院至专业护理机构比例(P=0.14)无差异。
  • 格拉斯哥昏迷评分≤8分亚组中,两组血肿进展(P=0.59)、神经外科干预(P=0.62)和死亡率(P=0.81)相似。

证据类型、等级与局限

  • 证据类型为治疗性研究,证据等级为III级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,初级保健医师和心脏科医师需要重新审视关于抗凝必要性和所用药物类型的资料,并权衡出血风险。
  • 作者认为,开发针对新型口服抗凝药的逆转剂并实施严格的逆转方案可能改善结局。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Novel oral anticoagulant (NOAC) use is increasing in trauma patients. The reversal of these agents after hemorrhage is still evolving. The aim of our study was to evaluate outcomes after traumatic brain injury in patients on NOACs.

METHODS: 3-year (2014-2016) analysis of our prospectively maintained traumatic brain injury (TBI) database. We included all TBI patients with intracranial hemorrhage (ICH) on anticoagulants. Patients were stratified into two groups, those on NOACs and on warfarin, and were matched in a 1:2 ratio using propensity score matching for demographics, injury and vital parameters, type, and size of ICH. Outcome measures were progression of ICH, mortality, skilled nursing facility (SNF) disposition, and hospital and intensive care unit (ICU) length of stay (LOS).

RESULTS: We analyzed 1,459 TBI patients, of which 210 patients were matched (NAOCs, 70; warfarin, 140). Matched groups were similar in age (p = 0.21), mechanism of injury (p = 0.61), Glasgow Coma Scale (GCS) score (p = 0.54), Injury Severity Score (p = 0.62), and type and size of ICH (p = 0.09). Patients on preinjury NOACs had higher rate of progression (p = 0.03), neurosurgical intervention (p = 0.04), mortality (p = 0.04), and longer ICU LOS (p = 0.04) compared with patients on warfarin. However, there was no difference in hospital LOS (p = 0.22) and SNF disposition (p = 0.14). On sub-analysis of severe TBI patients (GCS ≤ 8), rate of progression (p = 0.59), neurosurgical intervention (p = 0.62), or mortality (p = 0.81) was similar in both groups.

CONCLUSIONS: The use of NOACs generally carries a high risk of bleeding and can be detrimental in head injuries with ICH. NOAC use is associated with increased risk of progression of ICH, neurosurgical intervention, and mortality after a mild and moderate TBI. Primary care physicians and cardiologists need to reconsider the data on the need for anticoagulation and the type of agent used and weigh it against the risk of bleeding. In addition, development of reversal agents for the NOACs and implementation of a strict protocol for the reversal of these agents may lead to improved outcomes.

LEVEL OF EVIDENCE: Therapeutic studies, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Zeeshan M, Jehan F, O'Keeffe T, et al. The novel oral anticoagulants (NOACs) have worse outcomes compared with warfarin in patients with intracranial hemorrhage after TBI. J Trauma Acute Care Surg. 2018. PMID: 29851905. doi:10.1097/TA.0000000000001995

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。